Dimerix Limited reported earnings results for the six months ended December 31, 2018. For the period, the company reported operating loss of AUD 1.76 million as compared to AUD 1.86 million for the same period last year.

Dimerix Limited advise that 7 patients have been recruited into the 10 patient Phase 2 clinical trial in FSGS, and 10 patients into the 40 patient Phase 2b clinical trial in Diabetic Kidney Disease. No serious adverse safety related events have been reported to date in either trial. The recruitment rate for each trial picked up significantly in February, following the December/January holiday period where many sites were closed, and hope to maintain this momentum moving forward. Dimerix will provide additional recruitment updates in due course. The two clinical studies are both double-blind, randomised, placebo-controlled, crossover studies, evaluating the safety and efficacy of DMX-200 in patients who are receiving Irbesartan, the current standard of care for both FSGS and Diabetic Kidney Disease. Clinical trial sites were initiated, and patient recruitment commenced in September, and patient dosing has occurred in line with anticipated timelines.